Constantin A. Dasanu

Expanding indications of immune checkpoint inhibitors: a decade of success going strong.

Limited benefit in other cancer subsets highlights the need for biomarker discovery and optimization of therapeutic strategies, including addition of antibody-drug conjugates to ICIs, next-generation checkpoint modulation, personalized neoantigen vaccines, and engineered cellular immunotherapy.